Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. Lin TS, et al. Among authors: byrd jc. Leuk Lymphoma. 2009 Dec;50(12):1958-63. doi: 10.3109/10428190903186486. Leuk Lymphoma. 2009. PMID: 19860603 Free PMC article. Clinical Trial.
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA. Byrd JC, et al. Blood. 2003 Jan 1;101(1):6-14. doi: 10.1182/blood-2002-04-1258. Epub 2002 Jul 5. Blood. 2003. PMID: 12393429 Free article. Clinical Trial.
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. Marcucci G, et al. Among authors: byrd jc. Blood. 2003 Jan 15;101(2):425-32. doi: 10.1182/blood-2002-06-1899. Epub 2002 Aug 22. Blood. 2003. PMID: 12393493 Free article. Clinical Trial.
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC. Aron JL, et al. Among authors: byrd jc. Blood. 2003 Jul 15;102(2):652-8. doi: 10.1182/blood-2002-12-3794. Epub 2003 Mar 20. Blood. 2003. PMID: 12649137 Free article.
Advances in the therapy of chronic lymphocytic leukemia.
Johnson AJ, Mone AP, Abhyankar V, Byrd JC. Johnson AJ, et al. Among authors: byrd jc. Curr Opin Hematol. 2003 Jul;10(4):297-305. doi: 10.1097/00062752-200307000-00008. Curr Opin Hematol. 2003. PMID: 12799536 Review.
Rituximab in B-cell chronic lymphocytic leukemia.
Lin TS, Lucas MS, Byrd JC. Lin TS, et al. Among authors: byrd jc. Semin Oncol. 2003 Aug;30(4):483-92. doi: 10.1016/s0093-7754(03)00239-2. Semin Oncol. 2003. PMID: 12939717 Review.
858 results